Charité Universitätsmedizin Berlin | Deutsches Herzzentrum der Charité - Studienzentrale logo

Charité Universitätsmedizin Berlin | Deutsches Herzzentrum der Charité - Studienzentrale

Research site
(Unclaimed)
Location
Augustenburger Platz 1, Berlin, Berlin, Germany

Site insights

Top conditions

Top treatments

Corticosteroids
Dexamethasone
STAR-0215
PF-06863135
Docetaxel
Cyclosporine
Trifluridine
DAY101
Irinotecan
Tipracil

Parent organization

This site is a part of Charité Universitätsmedizin Berlin

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 8 total trials

A Study of STAR-0215 in Participants With Hereditary Angioedema

The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1...

Enrolling
Hereditary Angioedema
Drug: STAR-0215
Locations recently updated

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monothe...

Enrolling
Low-grade Glioma
Drug: Tovorafenib
Drug: Chemotherapeutic Agent

The Allo-RevCAR01-T-CD123 drug is a combination of a cellular component (Allo-RevCAR01-T) with a recombinant antibody derivative (R-TM123), which tog...

Enrolling
Acute Myeloid Leukemia Refractory
Acute Myeloid Leukemia, in Relapse
Drug: Allo-RevCAR01-T
Other: Cyclophosphamide (Non-IMP, Lymphodepletion)

A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in pati...

Enrolling
Acute-On-Chronic Liver Failure
Ascites
Other: SOC (Control Group)
Drug: VS-01 on top of SOC

The aim of the DigiNet project is to improve the treatment of patients with advanced non-small cell lung cancer (NSCLC) in Germany. The project promo...

Active, not recruiting
Non-small Cell Lung Cancer Stage IV
Other: DigiNet intervention

The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclo...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Pomalidomide

To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in...

Active, not recruiting
Gastro-Oesophageal Cancer
Biological: Nivolumab
Drug: Paclitaxel

Trial sponsors

A
A
D
Lilly logo
Pfizer logo
U
V
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems